Infectious disease molecular diagnostics market seen rising to $38.77 billion by 2030

The Business Research Company says the global infectious disease molecular diagnostics market will grow from $32.04 billion in 2026 to $38.77 billion by 2030. The report points to faster adoption of AI tools, point-of-care testing, multiplex assays and antimicrobial resistance detection as key growth drivers.

Why it matters: - Infectious disease molecular diagnostics are becoming a bigger part of how healthcare systems detect pathogens faster and guide treatment decisions. - The market's growth reflects rising infectious disease burden, stronger lab capabilities and demand for more precise testing. - The report's outlook suggests continued investment in technologies that can improve outbreak response, surveillance and clinical decision-making.

What happened: - The Business Research Company published an Infectious Disease Molecular Diagnostics Market Report 2026 covering market size, trends and global forecast through 2035. - The market is projected to rise from $30.46 billion in 2025 to $32.04 billion in 2026. - The report forecasts the market will reach $38.77 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.

The details: - Infectious disease molecular diagnostics detect and identify genetic material from bacteria, viruses, fungi and parasites in patient samples. - These tests support rapid and accurate diagnosis and can improve disease management outcomes. - The report links recent market growth to rising infectious disease prevalence, advances in PCR and sequencing technologies, increased government funding for research, greater awareness of early diagnosis and expansion of clinical laboratory networks. - The report expects growth to continue at a 4.9% CAGR through 2030. - The forecast also points to AI-powered diagnostic tools, demand for rapid and precise methods, healthcare infrastructure growth in emerging markets, personalized medicine and home-based molecular diagnostics. - Key trends expected to shape the market include point-of-care testing, multiplex testing, integration with electronic health record systems, broader surveillance efforts and antimicrobial resistance detection. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company offers a free sample of the report and the full market report.

Between the lines: - The report frames molecular diagnostics as a response to a growing global disease burden and faster pathogen spread tied to globalization and international travel. - The market shift toward AI, home testing and EHR integration suggests buyers want faster workflows and broader access, not just more accurate tests. - A 15.6% increase in U.S. tuberculosis cases, from 8,332 in 2022 to 9,633 in 2023, illustrates the demand backdrop the report highlights. - The regional outlook points to mature demand in North America and faster expansion in Asia-Pacific, where healthcare infrastructure is still developing.

What's next: - The market is likely to keep moving toward faster, decentralized and more integrated testing platforms. - Growth will likely depend on how quickly providers adopt multiplex, point-of-care and AI-enabled tools. - Expanded surveillance and antimicrobial resistance detection could become more important as health systems look to manage outbreaks earlier and more efficiently.

The bottom line: - Infectious disease molecular diagnostics are set for steady growth as health systems prioritize speed, accuracy and broader testing access.